Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Sohail Tavazoie
Rgenix, Inc., Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rgenix, Inc.
Payment for services (e.g., consulting fees, honoraria, paid authorship)
The Committee has determined that a conflict of interest exists with this grant. Rgenix is a privately held company licensing RU technology that focuses on generating first-in-class therapeutics that target key nodes in cancer progression, and this program is expected to benefit from information generated under this grant. Specifically, this project will directly validate the therapeutic efficacy of RGX-104, a Liver X Agonist that induces tumor-suppressing regulator ApoE. RGX-104 was developed as a new therapy for treatment of metastatic melanoma as part of Rgenix’s product pipeline, and as such, Rgenix may in the future benefit from these findings.
Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma
Project Narrative In this Direct-to-Phase II proposal, Rgenix plans to complete the pre-clinical development of RGX-104, a novel therapeutic that is developed for metastatic melanoma as well as for post-surgical adjuvant treatment as a means of preventing metastatic spread. Successful completion of the proposed studies will allow RGX-104 to enter human clinical trials. This project, when successful, will offer a novel and highly effective therapeutic for the treatment of Stage IIb-IV melanoma, which is diagnosed in 39,000 patients nationwide and is incurable for roughly a quarter of these patients.
Filed on August 10, 2017.
Tell us what you know about Sohail Tavazoie's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Sohail Tavazoie”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Sohail Tavazoie | Rgenix, Inc. | Conflict of Interest | Rgenix, Inc. | $500,000 - $549,999 |
| Sohail Tavazoie | Rgenix, Inc. | Conflict of Interest | The Rockefeller University | $500,000 - $549,999 |
| Sohail Tavazoie | Rgenix, Inc. | Conflict of Interest | Rgenix, Inc. | $500,000 - $549,999 |
| Sohail Tavazoie | Rgenix, Inc. | Conflict of Interest | The Rockefeller University | $40,000 - $59,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.